Rheumatoid Arthritis

Infusion Reactions in Patients With Rheumatic Diseases Treated in a Rheumatology Infusion Center (2016-2020)

Infusion Reactions in Patients With Rheumatic Diseases Treated in a Rheumatology Infusion Center (N=17042)

2016-2020

Infusion reaction definition:

  • Mild reaction = No infusion interruption
  • Moderate reaction = Infusion interruption but responsive to symptomatic treatment and able to continue infusion
  • Severe reaction = Anaphylaxis, prolonged reaction that is not rapidly responsive to symptomatic treatment that may require emergency response/hospitalization

The Rheumatology Infusion Center administered between 3033 and 3544 infusions in the period 2016-2020. Both biologic and nonbiologic medications were used to treat a large number of patients with rheumatic diseases. Infusion reactions can be serious complications and require established protocols to guarantee appropriate premedication, infusion rates, and treatment for drug reactions to ensure patient safety. In 2016, reactions occurred in 48 of 3033 infusions (1.6%), and were mild in 1, moderate in 45, and severe in 2 infusions. In 2017, reactions occurred in 80 of 3301 patients (2.4%), and were mild in 4, moderate in 75, and severe in 1 infusion. In 2018, reactions occurred in 51 of the 3544 patients (1.4%), and were mild in 4, moderate in 47, and severe in zero infusions. In 2019, reactions occurred in 79 of the 3681 patients (2.1%), and were mild in 4, moderate in 74, and severe in 1 infusion. In 2020, reactions occurred in 63 of the 3483 patients (2.0%), and were mild in 0, moderate in 61, and severe in 2 infusions. Only 15 patients were not able to complete the infusions (0.09%) in 2016-2020.